CN1128991A - N-取代的氮杂环羧酸及其酯 - Google Patents
N-取代的氮杂环羧酸及其酯 Download PDFInfo
- Publication number
- CN1128991A CN1128991A CN94193060A CN94193060A CN1128991A CN 1128991 A CN1128991 A CN 1128991A CN 94193060 A CN94193060 A CN 94193060A CN 94193060 A CN94193060 A CN 94193060A CN 1128991 A CN1128991 A CN 1128991A
- Authority
- CN
- China
- Prior art keywords
- compound
- phenyl
- formula
- carboxylic acid
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002148 esters Chemical class 0.000 title description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 52
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 15
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 10
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 6
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract description 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 4
- 125000005605 benzo group Chemical group 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- -1 benzylidene, phenyl Chemical group 0.000 claims description 20
- 239000001301 oxygen Substances 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- XJLSEXAGTJCILF-UHFFFAOYSA-N nipecotic acid Chemical compound OC(=O)C1CCCNC1 XJLSEXAGTJCILF-UHFFFAOYSA-N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 208000015114 central nervous system disease Diseases 0.000 claims 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 abstract description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 39
- 239000000203 mixture Substances 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 239000002904 solvent Substances 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000007787 solid Substances 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000007738 vacuum evaporation Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 7
- 235000015320 potassium carbonate Nutrition 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 229940091860 GABA uptake inhibitor Drugs 0.000 description 5
- 239000002843 gaba uptake inhibitor Substances 0.000 description 5
- 150000002923 oximes Chemical class 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000005660 chlorination reaction Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- QTDZOWFRBNTPQR-UHFFFAOYSA-N guvacine Chemical compound OC(=O)C1=CCCNC1 QTDZOWFRBNTPQR-UHFFFAOYSA-N 0.000 description 4
- RBLWMQWAHONKNC-UHFFFAOYSA-N hydroxyazanium Chemical compound O[NH3+] RBLWMQWAHONKNC-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001225 nuclear magnetic resonance method Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000001261 hydroxy acids Chemical group 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RWOLAHHEUZXIJZ-HBKPYOMSSA-N (ne)-n-[(2e)-2-benzylidenecyclohexylidene]hydroxylamine Chemical compound O\N=C\1/CCCC/C/1=C\C1=CC=CC=C1 RWOLAHHEUZXIJZ-HBKPYOMSSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- FEHZEROBXJXUCB-UHFFFAOYSA-N 1-ethylpiperidine-3-carboxylic acid;hydrochloride Chemical compound Cl.CCN1CCCC(C(O)=O)C1 FEHZEROBXJXUCB-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- DVIUIRUQKVUCNG-UHFFFAOYSA-N 2-phenyl-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CC2=CC=CC=C2C(=O)C1C1=CC=CC=C1 DVIUIRUQKVUCNG-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical class 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- XIWBSOUNZWSFKU-UHFFFAOYSA-N ethyl piperidine-3-carboxylate Chemical compound CCOC(=O)C1CCCNC1 XIWBSOUNZWSFKU-UHFFFAOYSA-N 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 1
- NAQQTJZRCYNBRX-UHFFFAOYSA-N n-pentan-3-ylidenehydroxylamine Chemical compound CCC(CC)=NO NAQQTJZRCYNBRX-UHFFFAOYSA-N 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001519 thymoleptic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明涉及有治疗活性的通式(I)氮杂环化合物，该化合物的制备方法，以及含有该化合物的药物组合物。这类新型化合物可用于治疗与GABA摄取有关的中枢神经系统失调。在通式(I)中,A是一个饱和或不饱和的5元或6元碳环，任选地可被一个苯基、亚苄基、苯基取代的C1-4烷基或苯基取代的C2-4链烯基取代，所述苯基或亚苄基可任选地被卤素、C1-4烷基、C1-4烷氧基或三氟甲基取代，且所述饱和或不饱和的5元或6元碳环可以任选地与一个苯并环稠合。
Description
发明领域
本发明涉及新型N-取代的氮杂环羧酸及其酯，其中一条有取代的烷基链形成该N-取代基及其盐的组成部分，涉及其制备方法，涉及含有这类化合物的组合物，及其在临床治疗γ-氨基丁酸神经传导系统的功能异常方面的用途。
发明背景
近年来，关于γ-氨基丁酸(以下简称GABA)这种哺乳动物中枢神经系统中的抑制性神经传递质，已经进行了大量药理学研究。
GABA摄取的抑制导致这种抑制性神经传递质在突触裂中的可得性提高，从而提高GABA能的活性(ergic activity)。GABA能的活性的提高可能有利于治疗诸如焦虑、疼痛和癫痫，以及肌肉和运动失调(例如，参阅P.Krogsgaard-Larsen et al.，Progress inMedicinal Chemistry，1985，22，68-112)。
从突触裂进入前突触神经末稍和胶质细胞的GABA摄取的一种众所周知和强力抑制剂，是诸如3-哌啶羧酸(3-哌啶甲酸)。然而，由于是一种相当极性的化合物，因而不能穿越血-脑屏障，3-哌啶羧酸本身不能发挥作为药物的实际效用。
在美国专利No.4,383,999和No.4,514,414以及EP236342和EP231996中，提出了N-(4，4-二取代-3-丁烯基)氮杂环羧酸的一些衍生物作为GABA摄取抑制剂的专利权。在EP342635和EP374801中，提出了肟醚基和乙烯醚基分别构成其N-取代基组成部分的N-取代杂环羧酸作为GABA摄取抑制剂的专利权。此外，在WO9107389和WO9220658中，提出了N-取代氮杂环羧酸作为GABA摄取抑制剂的专利权。EP221572声称1-芳氧烷基吡啶-3-羧酸是GABA摄取抑制剂。
按照Yunger，L.M.et al.，J.Pharm.Exp.Ther.，1984，228，109，N-(4，4-二苯基-3-丁烯-1-基)3-哌啶甲酸(取名为SK&F 89976A)，N-(4，4-二苯基-3-丁烯-1-基)四氢烟酸(取名为SK&F 100330A)，N-(4，4-二苯基-3-丁烯-1-基)高-β-脯氨酸(取名为SK&F 100561)和N-(4-苯基-4-(2-噻吩基)-3-丁烯-1-基)3-哌啶甲酸(取名为SK&F 100604J)是经口活性的GABA摄取抑制剂。这些资料已综合于Krogsgaard-Larsen，P.et al.，Epilepsy Res.，1987，1，77-93。
发明描述
本发明涉及新型N-取代氮杂环羧酸及其酯，其通式(I)为：
式中：
A是一个饱和或不饱和的5元或6元碳环，任选地可被一个苯基、亚苄基、苯基取代的C1-4烷基或苯基取代的C2-4链烯基取代，所述苯基或亚苄基可任选地被卤素、C1-4烷基、C1-4烷氧基或三氟甲基取代，且所述饱和或不饱和的5元或6元碳环可以任选地与一个苯并环稠合；
R1和R2代表氢，或可合在一起代表一个键；
X是羟基或C1-4烷氧基；
n是2、3、4或5；或其药物上可接受的盐。
通式I的化合物可以作为几何异构体和光学异构体存在，所有异构体及其混合物均包括在本发明范围内。异构体可借助于标准方法如色谱技术或适用盐的分级结晶进行分离。
按照本发明的化合物可从任选地以药物上可接受的酸加成盐形式存在，或当羧酸基团未被酯化时以药物上可接受金属盐形式存在，或任选地被烷基化时以铵盐形式存在。
这样的盐的实例包括无机酸和有机酸加成盐，例如盐酸盐、氢溴酸盐、硫酸盐、磷酸盐、乙酸盐、酞酸盐、富马酸盐、马为酸盐、柠檬酸盐、乳酸盐、酒石酸盐、草酸盐，或类似的药物上可接受的无机酸或有机酸加成盐，并包括列为本文参考文献的Tournal ofPharmaceutical Science，66，2(1977)中所列的药物上可接受的盐。
在本发明的一个较好实施方案中，C1-4烷基是甲基或乙基，C2-4链烯基是亚乙基，C1-4烷氧基是甲氧基或乙氧基，X包括甲氧基、乙氧基、异丙氧基或正丙氧基，且n包括2或3。
通式I化合物比无N-取代基的母体化合物(即哌啶甲酸和四氢烟酸)有更大的亲油性，因而对大脑有更大的有效性。
业已证明，对从突触裂摄取GABA有抑制作用的通式I新型化合物之所以在中枢神经系统中具有有用的药理学性质，是因为它们引起GABA的能活性的选择性增强。通式I化合物可以用来治疗诸如疼痛、焦虑、嘧啶过多性运动障碍、癫痫和某些肌肉与运动失调。它们也可用作镇静剂、安眠药和抗抑郁药。
通式I化合物是用如下方法制备的：
方法A：
通式II的化合物，式中A的定义同上，可以与通式III的氮杂环化合物反应，式中R1、R2、n和X的定义同上，且Z是一个适用离去基团如卤素、对甲苯磺酸根或甲磺酸根。这个烷基化反应可以在一种溶剂如丙酮、二丁基醚、2-丁酮、四氢呋喃、甲基异丁基酮或甲苯中，在一种碱如碳酸钾的存在下，在可高达所用溶剂的回流温度的温度，进行诸如1～120小时。如果已制备了其中X为烷氧基的酯，则其中X为OH的通式I化合物可以通过该酯基的水解来制备，较好在室温下，在碱金属氢氧化物水溶液和醇如甲醇或乙醇的混合物中进行诸如约0.5～6小时。
通式II的化合物可以容易地用技术熟练人员所熟悉的方法制备。通式III的化合物可以按照EP374801中描述的步骤制备。
在某些情况下，可能有必要用适用的保护基团来保护以上方法中使用的中间体，如通式III的化合物。例如，可以使该羧酸基团酯化。这样的基团的引进和脱除详见“Protective Groups in OrganicSynthesis”，T.W.Greene and P.G.M.Wuts，2ed.(John Wiley，1991)。
药理学方法
本发明化合物的[3H]-GABA摄取的离体抑制值基本上是用Fjalland的方法(Acta Pharmacol.Toxicol.1978，42，73-76)评价的。
雄性Wistar品系大鼠皮质组织用一台玻璃/PTFE匀化器，以10倍体积的0.32M蔗糖，用手徐徐匀化。用一种含有120nM NaCl、9.2nM KCl、4mM MgSO4、2.3nMCaCl2和10mM葡萄糖的40mMTRIS HCl缓冲剂(30℃ pH7.5)在30℃培养60分钟。
表1列出了一些代表性化合物的GABA摄取抑制值。
表1
[3H]-GABA摄取抑制值
实例号 离体IC50(μM)
1 332
2 417
3 9500
4 819
5 1380
对于以上指示值，剂量将因所采用的通式I化合物、给药方式和所希望的治疗而异。然而，一般来说，能得到令人满意的结果的剂量是约0.5mg～约1000mg、较好约1mg～约500mg通式I化合物，方便地每天给药1～5次，任选地以缓释形式。通常，适用于经口给药的剂量形式包含与药物载体或稀释剂掺合的约0.5mg～约1000mg、较好约1mg～约500mg通式I化合物。
通式I化合物可以以药物上可接受的酸加成盐形式，或在可能的情况下以金属盐或低级烷基铵盐形式给药。
本发明也涉及含有通式I化合物或其药物上可接受的盐的药物组合物，且通常这样的组合物也含有药物载体或稀释剂。含有本发明化合物的组合物可以用常用技术制备，并呈常用形式，例如胶囊、片剂、溶液或悬浮液。
采用的药物载体可以是常用固体载体或液体载体。固体载体的实例是乳糖、白土、蔗糖、滑石粉、明胶、琼脂、果胶、阿拉伯胶、硬脂酸镁和硬脂酸。液体载体的实例是糖浆、花生油、橄榄油和水。
类似地，载体或稀释剂可以包括任何一种技术上已知的延时材料，例如，甘油基一硬脂酸酯或甘油基二硬脂酸酯，单独或与蜡混合使用。
如果使用经口给药用的固体载体，则该制剂可制成片剂、以粉末或小丸形式放进硬胶囊胶中，也可以将其制成含片或糖锭形式。固体载体的用量差异很大，但通常将是约25mg～约1g。如果使用液体载体，则该制剂可制成糖浆、乳液、软胶囊或无菌可注射液体如水或非水液体悬浮液或溶液剂等形式。
一般来说，本发明的化合物是配制成单元剂量形式的，每单元剂量包含50～200mg活性组分或同时含有药物上可接受的载体。
按照本发明的化合物的剂量，当以药物形式对患者如人给药时，是1～500mg/日，例如，每剂约100mg。
一种可通过常用压片技术制备的典型片剂包含：
片芯：
活性化合物(游离化合物或其盐) 100mg
胶体二氧化硅(Aerosil) 1.5mg
微晶纤维素(Avicel) 70mg
改性纤维素胶(Ac-Di-Sol) 7.5mg
硬脂酸镁
包衣：
HPMC 大约9mg
*Mywacett9-40T 大约0.9mg
*酰化单甘油酯，用作薄膜包衣增塑剂。
给药途径可以是能有效地将该活性化合物输送到适当或预期作用部位的任何一种途径，例如经口或非经肠，如经直肠、经皮、经皮下、经静脉内、经肌内或经鼻内，较好是经口途径。
实例
以下实例进一步说明通式I化合物的制备方法，然而不要将其理解为限制。
下文中，TLC是薄层色谱法，THF是四氢呋喃，CDCl3是氘化氯仿，DMSO-d6是六氘二甲基亚砜。这些化合物的结构或者用元素分析法或者用NMR(核磁共振法)证实，在此情况下，只要适当，就列出标题化合物中特征质子对应的峰。NMR位移(δ)用ppm表示。M.p.是熔点，用℃表示。柱色谱法是用W.C.Still et al.，J.Org.Chem.，1978，43，2923-2925所述的技术(Art.9385)用Merck硅胶60进行的。用作起始原料的化合物或者是已知化合物，或者是可以容易地用本身已知的方法制备的化合物。
实例1
(R)-1-(2-(((2-苯基亚环己基)氨基)氧乙基)-3-哌啶羧酸盐酸盐
往搅拌着的2-苯基环乙酮(5.0g，29mmol)和氯化羟胺(6.0g，86mmol)在乙醇(20ml)和水(10ml)的混合物中的悬浮液中加入碳酸钾(11.9g，86mmol)的水(50ml)溶液。反应混合物在室温下搅拌5小时，过滤分离出沉淀；然后用水洗涤。在空气中干燥后得到5.1g固体状2-苯基环乙酮肟，m.p.159-160℃。
将上面的肟(2.0g，11mmol)、(R)-1-(2-溴乙基)-3-哌啶羧酸乙酯氢溴酸盐(3.7g，11mmol，EP374801)、碳酸钾(4.6g，33mmol)和丙酮(50ml)的混合物在室温下搅拌6天。将混合物过滤，溶剂进行真空蒸发。残留物用柱色谱法在硅胶上提纯两次(环己烷/乙酸乙酯，梯度3/1-1/1)得到0.65g(R)-1-2-(((2-苯基亚环己基)氨基)氧)乙基)-3-哌啶羧酸乙酯油状物。
将上面的酯(0.6g，1.6mmol)溶解在乙醇(5ml)中，加入4N氢氧化钠(1.6ml)。将混合物在室温下搅拌20小时，放在冰浴上，然后加入过量的浓盐酸。将混合物进行真空浓缩，然后加入二氯甲烷(300ml)。将各相分离，有机相用水(5ml)洗涤，然后干燥(MgSO4)。经真空蒸发掉溶剂后得到0.52g无定形固体标题化合物。M.p.43-45℃.计算值C20H28N2O3·HCl·1/4H2O：C，62.3％；H，7.7％；N，7.3％；实测值：C，62.4％；H，7.8％；N，7.2％。
实例2
(R)-1-(2-(((2-苯基亚环己-2-烯基)氨基)氧)乙基-3-哌啶羧酸盐酸盐
将2-苯基-2-环乙烯-1-酮(0.6g，3.5mmol，Tetrahedron1972，28，2369)、氯化羟铵(0.5g，7mmol)和无水吡啶(15ml)的混合物加热回流3小时。主反应混合物冷却，溶剂进行真空蒸发。将残留物溶于乙酸乙酯和水的混合物中。加入10％柠檬酸溶液直至显酸性pH为止，然后分离两相。有机相用10％柠檬酸溶液萃取，然后干燥(MgSO4)。在真空中蒸发掉溶剂后得到0.55g 2-苯基-2-环己烯-1-酮肟。m.p.144-146℃。
将上面的肟(0.55g，2.9mmol)、(R)-1-(2-溴乙基)-3-哌啶羧酸乙酯氢溴酸盐(1.0g，2.9mmol，EP374801A)、碳酸钾(1.0g，7.3mmol)和丙酮(25ml)的混合物在室温下搅拌14天。将混合物过滤，溶剂进行真空蒸发。残留物用柱色谱法在硅胶125g，(庚烷/乙酸乙酯＝1∶1)上提纯得到0.4g(R)-1-(2-(((2-苯基亚环己2-烯基)氨基)氧)乙基-3-哌啶羧酸乙酯油状物。
将上面的酯(0.4g，1.1mmol)溶解在乙醇(10ml)中，然后加入4N氢氧化钠(1ml)。该混合物在室温下搅拌3小时，然后加入过量的浓盐酸，接着加入二氯甲烷(400ml)。该悬浮液用MgSO4干燥，溶剂经真空蒸发。残留物与丙酮一起再蒸发，将其溶于丙酮(10ml)中，进行重结晶，得到1.7g固体标题化合物。M.p.171-172℃.计算值C20H25N2O3·HCl·1/4H2O：C，62.7％；H，7.2％；N，7.3％；实测值：C，63.0％；H，7.4％：N，6.9％。
实例3
(R)-1-(2-(((2-(亚苄基)亚环己基)氨基)氧)乙基)-3-哌啶羧酸盐酸盐
将2-亚苄基环己酮(3.5g，18.8mmol，J.Chem.Soc.1949，2957)、氯化羟铵(3.9g，56mmol)和乙醇(50ml)的混合物在室温下搅拌3天，在真空下蒸发掉溶剂，将残留物溶于乙酸乙酯(200ml)和水(50ml)的混合物中。将两相分离，水相用乙酸乙酯(50ml)萃取。合并的有机萃取物用水洗涤，用MgSO4干燥。在真空中蒸发掉溶剂后得到3.7g固体状2-亚苄基环己酮肟。m.p.114-115℃。
将上面的肟(3.7g，18.4mmol)、(R)-1-(2-溴乙基)-3-哌啶羧酸乙酯氢溴酸盐(7.0g，20.2mmol，EP374801)、碳酸钾(10.2g，73.5mmol)和丙酮(150ml)的混合物在室温下搅拌11天。将混合物过滤，溶剂进行真空蒸发。残留物用柱色谱法在硅胶(200g，庚烷/乙酸乙酯＝3/2)上提纯得到2.5g(R)-1-(2-(((2-(亚苄基)亚环己基)氨基)氧)乙基)-3-哌啶羧酸乙酯油状物。
将上面的酯(2.5g，6.5mmol)溶解在乙醇(20ml)中，然后加入4N氢氧化钠(4.9ml)。该混合物在室温下搅拌3小时，然后加入过量的浓盐酸，接着加入二氯甲烷(300ml)和水(15ml)。将两相分离，有机相用MgSO4干燥，溶剂经真空蒸发。残留物与丙酮一起再蒸发，然后用丙酮(180ml)重结晶，得到1.5g固体标题化合物。M.p.116℃分解.计算值C21H30N2O3·HCl：C，63.9％；H，7.9％；N，7.1％；实测值：C，63.9％：H，7.6％；N，6.9％。
实例4
(R)-1-(2-(((2-苯基-1，2，3，4-四氢-1-亚萘基)氨基)氧)乙基)-3-哌啶羧酸盐酸盐
将2-苯基-1-四氢萘酮(1.1g，5mmol，J.Am.Chem.Soc.1949，71，1092)、氯化羟铵(0.7g，10mmol)和无水吡啶(30ml)的混合物加热回流4小时，然后在室温下搅拌过夜。在真空中蒸发掉溶剂后将残留物在乙酸乙酯(50ml)和10％柠檬酸(50ml)的混合物中搅拌。将两相分离，有机相用水洗涤，然后用MgSO4干燥。在真空中蒸发掉溶剂后得到1.2g固体状2-苯基-1-四氢萘酮肟。m.p.156-157℃。
将上面的肟(1.0g，4.2mmol)、(R)-1-(2-溴乙基)-3-哌啶羧酸乙酯氢溴酸盐(2.2g，6.3mmol，EP374801)、碳酸钾(1.5g，11mmol)和丙酮(25ml)的混合物在室温下搅拌10天。将混合物过滤，溶剂进行真空蒸发。残留物用柱色谱在硅胶(150g，庚烷/乙酸乙酯＝7/3)上提纯得到0.6g(R)-1-(2-(((2-苯基-1，2，3，4-四氢-1-亚萘基)氨基)氧)乙基)-3-哌啶羧酸乙酯油状物。
将上面的酯(0.6g，1.51mmol)溶解在乙醇(10ml)中，然后加入4N氢氧化钠(1.1ml)。该混合物在室温下搅拌4小时，然后加入过量的浓盐酸，接着加入二氯甲烷(300ml)。混合物用MgSO4干燥，溶剂经真空蒸发。得到的残留物与丙酮一起再蒸发，然后用丙酮重结晶，得到0.5g固体标题化合物。M.p.160-162℃.计算值C24H28N2O3·HCl·H2O：C，66.5％；H，6.9％；N，6.5％；实测值：C，66.4％；H，6.8％；N，6.1％。
实例5
(R)-1-(2-(((3-苯基-1-(2，3-二氢化亚茚基))氨基)氧)乙基)-3-哌啶羧酸盐酸盐
将3-苯基-1-(2，3-二氢茚酮)(4.2g，20mmol，J.Chem.Soc.1949，2957)、氯化羟铵(2.8g，40mmol)和吡啶(30ml)的混合物加热回流加夜。让反应混合物冷却，在真空中蒸发掉溶剂。将残留物溶于乙酸乙酯中，然后用过量的10％柠檬酸溶液洗涤。有机相用MgSO4干燥。在真空中蒸发掉溶剂后得到的固体物用环己烷和乙酸乙酯的混合物研制。过滤分离出固体物，在空气中干燥后得到2.8g3-苯基-1-(2，3-二氢茚酮肟)。m.p.123-125℃。
将上面的肟(1.1g，5mmol)(R)-1-(2-溴乙基)-3-哌啶羧酸乙酯氢溴酸盐(1.7g，5mmol，EP374801)、碳酸钾(1.7g，13mmol)和丙酮(25ml)的混合物在室温下搅拌11天。将混合物过滤，溶剂进行真空蒸发。残留物用柱色谱法在硅胶(100g，庚烷/乙酸乙酯＝1/1)上提纯得到1.1g(R)-1-(2-(((3-苯基-1-(2，3-二氢化亚茚基)氨基)氧)乙基)-3-哌啶羧酸乙酯油状物。
将上面的酯(0.6g，1.5mmol)溶解在乙醇(15ml)中，然后加入4N氢氧化钠(1.1ml)。该混合物在室温下搅拌5小时，然后加入过量的浓盐酸，接着加入二氯甲烷(300ml)。将两相分离，有机相用MgSO4干燥，溶剂经真空蒸发。将残留物溶于丙酮(15ml)中，进行重结晶，得到0.6g固体标题化合物。M.p.204-205℃，计算值C23H26N2O3·HCl：C，66.6％；H，6.6％；N，6.8％；实测值：C，66.3％；H，6.6％：N，6.4％。
Claims (9)
1.式I的化合物或其药物上可接受的盐：
式中：
A是一个饱和或不饱和的5元或6元碳环，任选地可被一个苯基、亚苄基、苯基取代的C1-4烷基或苯基取代的C2-4链烯基取代，所述苯基或亚苄基可任选地被卤素、C1-4烷基、C1-4烷氧基或三氟甲基取代，且所述饱和或不饱和的5元或6元碳环可以任选地与一个苯并环稠合；
R1和R2代表氢，或可合在一起代表一个键；
X是羟基或C1-4烷氧基；
n是2、3、4或5。
2.按照权利要求1的化合物，该化合物是：
(R)-1-(2-(((2-苯基亚环己基)氨基)氧)乙基)-3-哌啶羧酸；
(R)-1-(2-(((2-苯基亚环己-2-烯基)氨基)氧)乙基)-3-哌啶羧酸；
(R)-1-(2-(((2-亚苄基)亚环己基)氨基)氧)乙基)-3-哌啶羧酸；
(R)-1-(2-(((2-苯基-1，2，3，4-四氢-1-亚萘基)氨基)氧)乙基)-3-哌啶羧酸；
(R)-1-(2-(((3-苯基-1-(2，3-二氢化亚茚基)氨基)氧)乙基)-3-哌啶羧酸；
或这些化合物的药物上可接受的盐。
3.权利要求1的化合物的制备方法，其特征在于：
a)使式II的化合物：
A＝N-OH(II)(其中A的定义同上)与式III的化合物反应，其中R1、R2、X和n的定义同上，Z是离去基团；或
b)使式I的化合物水解：
(其中A、R1、R2、和n的定义同上，X是C1-4烷氧基)，得到式I的化合物，其中A、R1、R2和n的定义同上，X是羟基。
4.以按照权利要求1的化合物为活性成分同时含有药物上可接受的载体或稀释剂的药物组合物。
5.含有有效量的权利要求1的化合物和药物上可接受的载体或稀释剂、适用于治疗与GABA摄取有关的中枢神经系统失调的药物组合物。
6.按照权利要求4或5的药物组合物，其中每单元剂量含有0.5mg～1000mg按照权利要求1的化合物。
7.对需要治疗的患者进行与GABA摄取有关中枢神经系统失调的治疗的方法，包括对所述患者施用有效量的按照权利要求1的化合物。
8.对需要治疗的患者进行与GABA摄取有关的中枢神经系统失调的治疗的方法，包括对所述患者施用按照权利要求5的药物组合物。
9.按照权利要求1的化合物用于制备治疗与GABA摄取有关的中枢神经系统失调的药剂的用途。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK0744/93 | 1993-06-23 | ||
| DK93744A DK74493D0 (da) | 1993-06-23 | 1993-06-23 | Novel heterocyclic chemistry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1128991A true CN1128991A (zh) | 1996-08-14 |
Family
ID=8097043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94193060A Pending CN1128991A (zh) | 1993-06-23 | 1994-06-22 | N-取代的氮杂环羧酸及其酯 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5639766A (zh) |
| EP (1) | EP0707568A1 (zh) |
| JP (1) | JPH08511781A (zh) |
| CN (1) | CN1128991A (zh) |
| AU (1) | AU6996094A (zh) |
| BG (1) | BG100245A (zh) |
| CA (1) | CA2165948A1 (zh) |
| CZ (1) | CZ335595A3 (zh) |
| DK (1) | DK74493D0 (zh) |
| FI (1) | FI956175A (zh) |
| HU (1) | HUT73242A (zh) |
| IL (1) | IL110076A0 (zh) |
| NO (1) | NO955261L (zh) |
| SK (1) | SK162395A3 (zh) |
| WO (1) | WO1995000484A1 (zh) |
| ZA (1) | ZA944468B (zh) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270488D0 (da) * | 1988-05-18 | 1988-05-18 | Novo Industri As | Hidtil ukendte o-substituerede ketoximer |
| DK93791D0 (da) * | 1991-05-17 | 1991-05-17 | Novo Nordisk As | Nye heterocykliske carboxylsyrer |
-
1993
- 1993-06-23 DK DK93744A patent/DK74493D0/da not_active Application Discontinuation
-
1994
- 1994-06-21 IL IL11007694A patent/IL110076A0/xx unknown
- 1994-06-22 CZ CZ953355A patent/CZ335595A3/cs unknown
- 1994-06-22 ZA ZA944468A patent/ZA944468B/xx unknown
- 1994-06-22 HU HU9503754A patent/HUT73242A/hu unknown
- 1994-06-22 WO PCT/DK1994/000251 patent/WO1995000484A1/en not_active Application Discontinuation
- 1994-06-22 US US08/263,863 patent/US5639766A/en not_active Expired - Fee Related
- 1994-06-22 CA CA002165948A patent/CA2165948A1/en not_active Abandoned
- 1994-06-22 SK SK1623-95A patent/SK162395A3/sk unknown
- 1994-06-22 CN CN94193060A patent/CN1128991A/zh active Pending
- 1994-06-22 AU AU69960/94A patent/AU6996094A/en not_active Abandoned
- 1994-06-22 JP JP7502351A patent/JPH08511781A/ja active Pending
- 1994-06-22 EP EP94918774A patent/EP0707568A1/en not_active Withdrawn
-
1995
- 1995-12-21 BG BG100245A patent/BG100245A/xx unknown
- 1995-12-21 FI FI956175A patent/FI956175A/fi unknown
- 1995-12-22 NO NO955261A patent/NO955261L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK162395A3 (en) | 1996-09-04 |
| EP0707568A1 (en) | 1996-04-24 |
| NO955261D0 (no) | 1995-12-22 |
| CA2165948A1 (en) | 1995-01-05 |
| WO1995000484A1 (en) | 1995-01-05 |
| ZA944468B (en) | 1995-12-22 |
| HUT73242A (en) | 1996-07-29 |
| AU6996094A (en) | 1995-01-17 |
| DK74493D0 (da) | 1993-06-23 |
| BG100245A (en) | 1996-05-31 |
| CZ335595A3 (en) | 1996-07-17 |
| NO955261L (no) | 1996-02-22 |
| IL110076A0 (en) | 1994-10-07 |
| FI956175A0 (fi) | 1995-12-21 |
| HU9503754D0 (en) | 1996-02-28 |
| US5639766A (en) | 1997-06-17 |
| FI956175A (fi) | 1996-02-21 |
| JPH08511781A (ja) | 1996-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2531565B2 (ja) | ３−アミノピペリジン誘導体及び関連する窒素含有複素環化合物 | |
| JP3238414B2 (ja) | トロパン―誘導体、その製造方法及びその使用方法 | |
| CN1167703C (zh) | 氮杂二环氨基甲酸酯及其作为α-7烟碱性乙酰胆碱受体激动剂的用途 | |
| US20070197601A1 (en) | Use of N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives in therapy | |
| CN1882540A (zh) | N－[苯基(哌啶－2－基)甲基]苯甲酰胺衍生物、其制备以及其治疗用途 | |
| HU229794B1 (hu) | Katekolamin prodrug fenil-etil-aminok és kondenzált gyûrûs származékaik, valamint ezek alkalmazása és ezeket tartalmazó gyógyszerkészítmények | |
| CN102639526B (zh) | 作为5-ht4受体配体的1,2-二氢-2-氧代喹啉化合物 | |
| JPH11503127A (ja) | 新規なヘテロ環式化合物 | |
| CN1127114A (zh) | 取代的4-苯基-6-氨基烟酸衍生物作为药物的应用 | |
| US6303627B1 (en) | Inhibitors of serotonin reuptake | |
| EP1135357B1 (en) | Process for the resolution of tramadol | |
| EP0399414A1 (en) | Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same | |
| CN1128989A (zh) | N-取代的氮杂环羧酸及其酯 | |
| CN1043609C (zh) | 含苯并噻唑类化合物的药物组合物的制备方法 | |
| CN1230959A (zh) | N－(2－苯并噻唑基)－1－哌啶乙胺衍生物,其制备方法及其在治疗中的应用 | |
| CN1128991A (zh) | N-取代的氮杂环羧酸及其酯 | |
| JP2010535174A (ja) | Ｎ−ピペリジン−４−イルメチルアミド誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのその使用 | |
| CN1128988A (zh) | N-取代的氮杂环羧酸及其酯 | |
| EP0850234B1 (en) | Novel heterocyclic compounds for the treatment of pain and use thereof | |
| JP3047112B2 (ja) | 置換アリールアミン類およびヘテロアリールアミン類、それらの製造方法、およびそれらの薬理組成物 | |
| CN1093089A (zh) | 头孢菌素盐类及制备方法 | |
| CN1902199A (zh) | 有抗疟活性的4－氨基－喹啉喹嗪啶基－和喹嗪啶烷基－衍生物 | |
| US20160168092A1 (en) | Process For The Preparation Of High Purity Miglustat | |
| CN1310707A (zh) | 新颖2,3,3a,4,9,9a－六氢－8－羟基－1h－苯并[f]吲哚,其制备方法及其作为药物的用途 | |
| CN85103930A (zh) | 制备止泻剂的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |